JP2021532774A5 - - Google Patents
Info
- Publication number
- JP2021532774A5 JP2021532774A5 JP2021505272A JP2021505272A JP2021532774A5 JP 2021532774 A5 JP2021532774 A5 JP 2021532774A5 JP 2021505272 A JP2021505272 A JP 2021505272A JP 2021505272 A JP2021505272 A JP 2021505272A JP 2021532774 A5 JP2021532774 A5 JP 2021532774A5
- Authority
- JP
- Japan
- Prior art keywords
- mica
- sequences
- monoclonal antibodies
- monoclonal
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023179043A JP7734720B2 (ja) | 2018-07-31 | 2023-10-17 | Ｍｉｃａ／ｂシェディングをブロックする抗ｍｉｃａ／ｂ抗体および使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862712608P | 2018-07-31 | 2018-07-31 | |
| US62/712,608 | 2018-07-31 | ||
| PCT/US2019/044234 WO2020028428A2 (en) | 2018-07-31 | 2019-07-30 | Anti-mica/b antibodies that block mica/b shedding and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023179043A Division JP7734720B2 (ja) | 2018-07-31 | 2023-10-17 | Ｍｉｃａ／ｂシェディングをブロックする抗ｍｉｃａ／ｂ抗体および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021532774A JP2021532774A (ja) | 2021-12-02 |
| JP2021532774A5 true JP2021532774A5 (https=) | 2022-09-08 |
| JP7370376B2 JP7370376B2 (ja) | 2023-10-27 |
Family
ID=69231308
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021505272A Active JP7370376B2 (ja) | 2018-07-31 | 2019-07-30 | Ｍｉｃａ／ｂシェディングをブロックする抗ｍｉｃａ／ｂ抗体および使用方法 |
| JP2023179043A Active JP7734720B2 (ja) | 2018-07-31 | 2023-10-17 | Ｍｉｃａ／ｂシェディングをブロックする抗ｍｉｃａ／ｂ抗体および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023179043A Active JP7734720B2 (ja) | 2018-07-31 | 2023-10-17 | Ｍｉｃａ／ｂシェディングをブロックする抗ｍｉｃａ／ｂ抗体および使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12065493B2 (https=) |
| EP (1) | EP3830128A4 (https=) |
| JP (2) | JP7370376B2 (https=) |
| KR (1) | KR102832008B1 (https=) |
| CN (2) | CN119930819A (https=) |
| AU (1) | AU2019312565B2 (https=) |
| CA (1) | CA3108022A1 (https=) |
| IL (1) | IL280487B2 (https=) |
| MX (1) | MX2021001254A (https=) |
| MY (1) | MY207765A (https=) |
| PH (1) | PH12021550232A1 (https=) |
| SG (1) | SG11202100981TA (https=) |
| WO (1) | WO2020028428A2 (https=) |
| ZA (1) | ZA202101258B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021001254A (es) | 2018-07-31 | 2021-05-12 | Cullinan Mica Corp | Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso. |
| KR20230152783A (ko) | 2020-07-07 | 2023-11-03 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
| CN115611982B (zh) * | 2021-07-14 | 2024-05-10 | 浙江大学 | 一种抗人MICA/Bα3区的单克隆抗体及其应用 |
| CN114369161B (zh) * | 2021-12-28 | 2023-06-23 | 合肥天港免疫药物有限公司 | Mica抗体及其应用 |
| CN114369162B (zh) * | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| US20250340651A1 (en) * | 2022-07-28 | 2025-11-06 | Cullinan Mica Corporation | Anti-mica/b antibodies with enhanced effector function and methods of use |
| CN118027195B (zh) | 2023-05-06 | 2025-07-04 | 合肥天港免疫药物有限公司 | 亲和力成熟的mica抗体及其应用 |
| CN119569886A (zh) | 2023-09-06 | 2025-03-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| WO2025085672A1 (en) * | 2023-10-17 | 2025-04-24 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2483343A1 (en) | 2002-04-22 | 2003-10-30 | Fred Hutchinson Cancer Research Center | Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions |
| EP2289534B1 (en) | 2004-04-05 | 2017-08-30 | The Regents of The University of California | NKG2D antibodies for use in the treatment of rheumatoid arthritis or Crohn's disease |
| US8716195B2 (en) * | 2005-11-14 | 2014-05-06 | Bioren, Inc. | Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening |
| EP1857116A1 (en) | 2006-05-19 | 2007-11-21 | Novoplant GmbH | Antigen binding polypeptides against spike glycoprotein (S2) of bovine coronavirus |
| CA3011859A1 (en) | 2007-04-23 | 2008-10-30 | Fred Hutchinson Cancer Research Center | Negative immunomodulation of immune responses by erp5 |
| HUE034044T2 (en) | 2011-09-30 | 2018-01-29 | Dana Farber Cancer Inst Inc | Therapeutic peptides |
| AU2013218017B2 (en) * | 2012-02-07 | 2017-12-07 | Innate Pharma | MICA binding agents |
| US20150044224A1 (en) | 2012-03-02 | 2015-02-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Materials and methods for differential treatment of cancer |
| CA2896058A1 (en) * | 2012-12-24 | 2014-07-03 | Abbvie Inc. | Prolactin receptor binding proteins and uses thereof |
| WO2014140884A2 (en) | 2013-03-15 | 2014-09-18 | Novelogics Biotechnology, Inc. | Methods and devices for removal of immunosuppressive ligands |
| EP2970490A4 (en) | 2013-03-15 | 2017-04-26 | Novelogics Biotechnology, Inc. | Antibodies to mica and micb proteins |
| WO2014190914A1 (en) | 2013-05-30 | 2014-12-04 | The University Of Hong Kong | Materials and methods for treatment of liver cancer background of the invention |
| AU2015264114A1 (en) | 2014-05-21 | 2016-11-03 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer with anti BiP or anti MICA antibodies |
| EP3430047A1 (en) * | 2016-03-15 | 2019-01-23 | Innate Pharma | Anti-mica antibodies |
| WO2017209318A1 (ko) * | 2016-05-30 | 2017-12-07 | 다이노나(주) | 탄산탈수소화 효소에 결합하는 항체 및 이의 용도 |
| US11780924B2 (en) | 2016-06-21 | 2023-10-10 | University Of Oslo | HLA binding vaccine moieties and uses thereof |
| EP3293271A1 (en) | 2016-09-12 | 2018-03-14 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Marker and target as a diagnostic variable and target for therapy of metastatic cancer |
| CA3040421A1 (en) | 2016-10-19 | 2018-04-26 | Novelogics Biotechnology, Inc. | Antibodies to mica and micb proteins |
| WO2018081648A2 (en) | 2016-10-29 | 2018-05-03 | Genentech, Inc. | Anti-mic antibidies and methods of use |
| EP3577138A1 (en) | 2017-02-06 | 2019-12-11 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| CN112566659A (zh) | 2018-01-25 | 2021-03-26 | 库利南Mica公司 | Mica/b抗体和使用方法 |
| EP3768715A1 (en) | 2018-03-23 | 2021-01-27 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| EP3773676A4 (en) | 2018-04-03 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams |
| MX2021001254A (es) | 2018-07-31 | 2021-05-12 | Cullinan Mica Corp | Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso. |
| WO2020035345A1 (en) | 2018-08-14 | 2020-02-20 | Innate Pharma | Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody |
-
2019
- 2019-07-30 MX MX2021001254A patent/MX2021001254A/es unknown
- 2019-07-30 SG SG11202100981TA patent/SG11202100981TA/en unknown
- 2019-07-30 EP EP19844652.8A patent/EP3830128A4/en active Pending
- 2019-07-30 JP JP2021505272A patent/JP7370376B2/ja active Active
- 2019-07-30 IL IL280487A patent/IL280487B2/en unknown
- 2019-07-30 MY MYPI2021000501A patent/MY207765A/en unknown
- 2019-07-30 CA CA3108022A patent/CA3108022A1/en active Pending
- 2019-07-30 AU AU2019312565A patent/AU2019312565B2/en active Active
- 2019-07-30 CN CN202510009976.3A patent/CN119930819A/zh active Pending
- 2019-07-30 KR KR1020217005972A patent/KR102832008B1/ko active Active
- 2019-07-30 WO PCT/US2019/044234 patent/WO2020028428A2/en not_active Ceased
- 2019-07-30 CN CN201980062628.5A patent/CN113056484B/zh active Active
-
2021
- 2021-01-29 US US17/162,585 patent/US12065493B2/en active Active
- 2021-01-29 PH PH12021550232A patent/PH12021550232A1/en unknown
- 2021-02-24 ZA ZA2021/01258A patent/ZA202101258B/en unknown
-
2023
- 2023-10-17 JP JP2023179043A patent/JP7734720B2/ja active Active
-
2024
- 2024-06-23 US US18/751,276 patent/US20250034262A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532774A5 (https=) | ||
| JP2019524645A5 (https=) | ||
| JP2021518135A5 (https=) | ||
| MA55363A (fr) | Anticorps multispécifiques egfr x cd28 | |
| JP2018024670A5 (https=) | ||
| JP2019124943A5 (https=) | ||
| JP2018203763A5 (https=) | ||
| JP2018116258A5 (https=) | ||
| JP2019164961A5 (https=) | ||
| EP4081547A4 (en) | Novel anti-fgfr2b antibodies | |
| JP2021503553A5 (https=) | ||
| JP2020183924A5 (https=) | ||
| JP2020175021A5 (https=) | ||
| JP2017227899A5 (https=) | ||
| JP2019519502A5 (https=) | ||
| JP2018186811A5 (https=) | ||
| JP2021163968A5 (https=) | ||
| JP2021512134A5 (https=) | ||
| JP2019152457A5 (https=) | ||
| EP4081539A4 (en) | Novel anti-fgfr2b antibodies | |
| JP2022027575A5 (https=) | ||
| JP2020049413A5 (https=) | ||
| JP2020043052A5 (https=) | ||
| JP2020180208A5 (https=) | ||
| JP2023005703A5 (https=) |